Open House Original Discount Contracts for Abemaciclib (2025-2028)

The Techniker Krankenkasse (TK) aims to establish discount contracts with all suitable pharmaceutical companies for the active ingredient Abemaciclib, in accordance with § 130c Abs. 1 SGB V. This contract will be part of TK's Open House Original procedure, where individual negotiations on contract terms will not be conducted, and uniform conditions will apply. TK does not guarantee exclusivity to any individual contracting partner. The contract duration is a maximum of 24 months, starting from November 1, 2025, and will end no later than October 31, 2027, regardless of the contract signing date. If the patent expires or market exclusivity ends before the stated end date, the contract will automatically terminate at the end of the month in which the patent or market exclusivity expires. Participation in this Open House Original procedure is possible at any time during the contract duration. Due to existing industrial property rights concerning the active ingredient or the relevant combination of active ingredients, participation and contract documents will only be provided to those pharmaceutical companies that offer or intend to offer medicines containing the relevant active ingredient or combination during the contract duration. The stated binding period is not relevant in this context and is solely due to the mandatory requirements of the form. All further information can be found in the participation and contract documents.